Structures by: Desper J.
Total: 512
TW-Pyr-bis-N-oxide 2,3,5,6-Me4-pyrazine-1,4-dioxideC8 H12 N2 O2
C8H12N2O2
Chemical communications (Cambridge, England) (2015) 51, 12 2425-2428
a=3.8328(9)Å b=10.291(3)Å c=10.396(3)Å
α=90.00° β=98.770(9)° γ=90.00°
JB-1-2 pyrazine 1-oxide, I-(CF2)4-I
(C4H4N2O)(C4F8I2)
Chemical communications (Cambridge, England) (2015) 51, 12 2425-2428
a=5.3515(5)Å b=11.1482(11)Å c=12.0159(12)Å
α=85.076(2)° β=80.408(3)° γ=84.424(2)°
JB-1-34 2,3,5,6-Me4-pyrazine-1,4-dioxide, I-(CF2)4-I
(C8H12N2O2)(C4F8I2)
Chemical communications (Cambridge, England) (2015) 51, 12 2425-2428
a=9.3817(10)Å b=12.8620(14)Å c=8.1127(9)Å
α=90.00° β=110.521(3)° γ=90.00°
Isonicotinamide, I2
(C6H6N2O)(I2)
Chemical Communications (Cambridge, United Kingdom) (2007) 41 4236-4238
a=7.6928(10)Å b=7.7411(10)Å c=8.1841(11)Å
α=80.734(2)° β=72.131(2)° γ=85.702(2)°
2(C6H6N2O),C6F4I2
2(C6H6N2O),C6F4I2
Chemical Communications (Cambridge, United Kingdom) (2007) 41 4236-4238
a=20.247(3)Å b=5.0710(9)Å c=21.279(3)Å
α=90.00° β=106.911(6)° γ=90.00°
3,3'-(phenanthrenol imine)-2,2'-binaphthyl
C50H32N2O2
Chemical Communications (2005) 37 4693-4695
a=11.0977(6)Å b=16.4934(10)Å c=18.7071(11)Å
α=90.00° β=90.00° γ=90.00°
Fe(ii)/binaphthyl bis(phenanthrenolate)imine
(C50H30N2O2Fe)(CH2Cl2)
Chemical Communications (2005) 37 4693-4695
a=13.1443(12)Å b=16.4557(15)Å c=18.9601(17)Å
α=99.736(6)° β=104.006(6)° γ=94.156(4)°
2,2'-bis(2-(1-oxy-2-phenanthrenyl)-1-azaethenyl)(1,1'- binaphthyl)zinc(ii)
(C50H30N2O2Zn1)(C1H4O1)(C1H3O1)0.75(C1H2Cl2)0.25
Chemical Communications (2005) 37 4693-4695
a=12.3373(4)Å b=13.3410(5)Å c=23.6254(8)Å
α=90.00° β=90.00° γ=90.00°
Bis[N-(3-pyridyl)acetamide], 1,4-diiodotetrafluorobenzene
(C7H8N2O)2(C6F4I2)
CrystEngComm (2008) 10, 12 1816
a=4.2616(9)Å b=29.232(6)Å c=17.734(4)Å
α=90.00° β=90.860(4)° γ=90.00°
2-(4-pyridyl)benzimidazole, 1,4-diiodotetrafluorobenzene, methanol
(C12H9N3)(C6F4I2)(CH4O)
CrystEngComm (2008) 10, 12 1816
a=9.0808(7)Å b=16.3144(12)Å c=13.6934(9)Å
α=90.00° β=91.057(4)° γ=90.00°
Bis{N-[(3-pyridyl)methyl]acetamide}, 1,4-diiodotetrafluorobenzene
(C8H10N2O)2(C6F4I2)
CrystEngComm (2008) 10, 12 1816
a=4.845(2)Å b=9.716(4)Å c=13.075(6)Å
α=104.096(6)° β=98.360(6)° γ=91.246(6)°
4-(pyrazol-3-yl)pyridine, 1,4-diiodotetrafluorobenzene
(C8H7N3)(C6F4I2)
CrystEngComm (2008) 10, 12 1816
a=7.1917(5)Å b=24.644(2)Å c=8.7269(7)Å
α=90.00° β=100.535(5)° γ=90.00°
[(5-OMe-3-pyridyl)(3-pyridyl)ethyne]4, [1,4-I2-F4-benzene]4
(C13H10N2O)4(C6F4I2)3
CrystEngComm (2008) 10, 12 1816
a=7.6881(4)Å b=14.8996(8)Å c=15.3296(8)Å
α=72.1600(10)° β=88.3640(10)° γ=88.5080(10)°
(pyridine-3,5-COOH) (2-AcNH-pyr)2, (1,4-I2-F4-benzene)2
(C7H5NO4)(C7H8N2O)2(C6F4I2)2
CrystEngComm (2008) 10, 12 1816
a=30.345(2)Å b=4.1878(3)Å c=16.6946(12)Å
α=90.00° β=90.00° γ=90.00°
(5-methoxy-3,3'-bipyridyl)2, (1,4-diiodotetrafluorobenzene)3
(C11H10N2O)2(C6F4I2)3
CrystEngComm (2008) 10, 12 1816
a=7.2012(7)Å b=17.6878(15)Å c=17.7138(16)Å
α=89.927(4)° β=82.869(7)° γ=88.275(6)°
1-(4-methoxyphenyl)-1,5-dihydro-5H-tetrazolone
C8H8N4O2
CrystEngComm (2009) 11, 9 1892
a=10.1689(3)Å b=6.9582(2)Å c=12.1607(4)Å
α=90.00° β=104.7990(10)° γ=90.00°
HG864A 2-(3-methoxyphenyl)-5-methyl-tetrazolone
C9H10N4O2
CrystEngComm (2009) 11, 9 1892
a=8.8329(5)Å b=13.1354(8)Å c=16.0027(9)Å
α=90.00° β=90.00° γ=90.00°
1-(4-methoxyphenyl)-4-methyl-1,5-dihydro-5H-tetrazolone
C9H10N4O2
CrystEngComm (2009) 11, 9 1892
a=3.8317(3)Å b=13.8861(13)Å c=17.7714(16)Å
α=90.00° β=90.00° γ=90.00°
HG-I1 N-(m-methoxyphenyl)tetrazolone
C8H8N4O2
CrystEngComm (2009) 11, 9 1892
a=12.414(11)Å b=19.068(16)Å c=7.190(6)Å
α=90.00° β=99.28(2)° γ=90.00°
(4-bromo-PhC(CN)(=NOH)), 3-bromo-5-methoxypyridine
(C8H5BrN2O)(C6H6BrNO)
CrystEngComm (2009) 11, 3 439-443
a=6.9907(6)Å b=8.0552(7)Å c=15.3027(13)Å
α=79.305(5)° β=89.038(5)° γ=64.660(5)°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)-2- methylbenzimidazole
(C8H5BrN2O)(C15H13BrN2)
CrystEngComm (2009) 11, 3 439-443
a=4.9374(6)Å b=22.597(3)Å c=19.233(2)Å
α=90.00° β=96.869(2)° γ=90.00°
4-bromo-PhC(CN)(N=OH), (3-((5,6-dimethylbenzimidazol-1- yl)methyl)PhCN
(C8H5N2OBr)(C17H15N3)
CrystEngComm (2009) 11, 3 439-443
a=6.039(3)Å b=13.982(6)Å c=14.166(6)Å
α=70.067(19)° β=83.78(3)° γ=82.22(3)°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)benzimidazole
(C8H5BrN2O)(C14H11BrN2)
CrystEngComm (2009) 11, 3 439-443
a=5.3033(6)Å b=13.2294(15)Å c=15.0601(17)Å
α=102.536(2)° β=99.505(2)° γ=94.752(2)°
(2-fluoro-PhC(CN)(=NOH))2, 1,2-di(4-pyridyl)ethene
(C8H5N2OF)2(C12H10N2)
CrystEngComm (2009) 11, 3 439-443
a=3.8189(6)Å b=11.2941(18)Å c=14.107(2)Å
α=98.884(10)° β=93.147(11)° γ=94.624(10)°
481 1,4-di((1-benzimidazolyl)methyl)benzene, (3-chloro- PhC(CN)(=NOH))2
(C22H18N4)(C8H5N2OCl)2
CrystEngComm (2009) 11, 3 439-443
a=13.6335(10)Å b=4.4402(3)Å c=27.297(2)Å
α=90.00° β=94.084(3)° γ=90.00°
MS 512 1-(4-pyridylmethyl)-5,6-Me2benzimidazole, 4-F- PhC(CN)(NOH)
(C15H15N3)(C8H5N2OF)
CrystEngComm (2009) 11, 3 439-443
a=16.1659(12)Å b=6.4146(5)Å c=21.0074(16)Å
α=90.00° β=105.945(5)° γ=90.00°
1,4-bis((1-pyrazolyl)methyl)benzene, (3,5-dinitrobenzoic acid)2
(C14H14N4)(C7H4N2O6)2
CrystEngComm (2006) 8, 8 586
a=12.526(3)Å b=10.179(2)Å c=12.332(3)Å
α=90.00° β=115.038(4)° γ=90.00°
MF142Me8 1,4-bis((3,5-dimethylpyrazol-1-yl)methyl)benzene, (2,6-Cl2PhCOOH)2
(C18H22N4)(C7H4Cl2O2)2
CrystEngComm (2006) 8, 8 586
a=7.5783(8)Å b=7.9010(9)Å c=14.1442(13)Å
α=103.784(7)° β=101.429(7)° γ=90.509(6)°
MF142Me8 1,4-bis((3,5-dimethylpyrazol-1-yl)methyl)benzene (Me5-PhCOOH)2
(C18H22N4)(C12H16O2)2
CrystEngComm (2006) 8, 8 586
a=8.8093(6)Å b=14.7493(10)Å c=15.4238(12)Å
α=67.222(4)° β=82.777(4)° γ=86.232(4)°
2-(4-(dimethylamino)phenylazo)benzoic acid, 3,5- dinitrobenzoic acid
(C15H15N3O2)(C7H4N2O6)
CrystEngComm (2004) 6, 5 19-24
a=7.0051(5)Å b=8.6187(7)Å c=18.5866(15)Å
α=101.186(2)° β=97.114(2)° γ=101.401(2)°
Isonicotinamide, 4-fluorobenzoic acid
(C6H6N2O)(C7H5FO2)
CrystEngComm (2004) 6, 5 19-24
a=22.725(13)Å b=5.231(3)Å c=20.785(12)Å
α=90.00° β=95.402(11)° γ=90.00°
4-nitrobenzoic acid, 3-(dimethylamino)benzoic acid
(C7H5NO4)(C9H11NO2)
CrystEngComm (2004) 6, 5 19-24
a=7.1538(13)Å b=7.9978(15)Å c=14.315(3)Å
α=91.111(3)° β=91.483(4)° γ=111.582(3)°
3,5-dinitrobenzamide, 4-(dimethylamino)benzoic acid
(C7H5N3O5)(C9H11NO2)
CrystEngComm (2004) 6, 5 19-24
a=8.0266(14)Å b=8.5974(16)Å c=12.514(2)Å
α=84.563(3)° β=89.934(4)° γ=75.345(3)°
AR-ZZ4 pentyl 4-pyridyl cavitand, 1,4-I2-F4-benzene
(C72H76N4O8)(C6F4I2)2(C2H3N)2
CrystEngComm (2012) 14, 20 6366
a=12.3175(5)Å b=13.2596(6)Å c=25.4769(11)Å
α=88.893(2)° β=88.152(2)° γ=79.980(2)°
C159H160.5F16I4N9.5O16
C159H160.5F16I4N9.5O16
CrystEngComm (2012) 14, 20 6366
a=18.758(3)Å b=19.828(3)Å c=22.558(3)Å
α=100.106(10)° β=98.682(10)° γ=110.342(9)°
Pyrazinecarboxamide, 4-nitrobenzamide
(C5H5N3O)(C7H6N2O3)
CrystEngComm (2004) 6, 5 19-24
a=7.6155(7)Å b=7.6980(9)Å c=21.587(2)Å
α=95.590(8)° β=94.719(7)° γ=90.268(8)°
Bis(N-(3-pyridyl)acetamide) fumaric acid
(C7H8N2O)2(C4H4O4)
CrystEngComm (2007) 9, 1 46
a=17.930(4)Å b=3.9380(10)Å c=25.723(6)Å
α=90.00° β=90.00° γ=90.00°
N-(4-pyridyl)acetamide, glutaric acid
(C7H8N2O)(C5H8O4)
CrystEngComm (2007) 9, 1 46
a=7.1730(8)Å b=7.6117(8)Å c=11.9194(13)Å
α=80.462(7)° β=75.807(7)° γ=87.896(7)°
(N-((4-pyridyl)methyl)acetamide)2, fumaric acid
(C8H10N2O)2(C4H4O4)
CrystEngComm (2007) 9, 1 46
a=4.9718(10)Å b=7.0047(11)Å c=15.101(2)Å
α=77.032(10)° β=89.414(12)° γ=82.324(12)°
N-(4-pyridyl)acetamide, sebacic acid
(C7H8N2O)2(C10H18O4)
CrystEngComm (2007) 9, 1 46
a=28.532(3)Å b=8.2965(8)Å c=10.6120(10)Å
α=90.00° β=101.987(2)° γ=90.00°
4-(acetamidomethyl)pyridine, adipic acid
(C8H10N2O)2(C6H10O4)
CrystEngComm (2007) 9, 1 46
a=4.7523(7)Å b=24.295(3)Å c=10.0355(12)Å
α=90.00° β=97.944(10)° γ=90.00°
(4-(aminomethyl)pyridine acetate)2, isophthalic acid
(C8H6O4)(C8H10N2O)2
CrystEngComm (2007) 9, 1 46
a=34.784(6)Å b=57.476(12)Å c=4.7674(9)Å
α=90.00° β=90.00° γ=90.00°
N-(4-pyridylmethyl)acetamide, 5-nitroisophthalic acid hydrate
(C8H10N2O)(C8H5NO6)(H2O)
CrystEngComm (2007) 9, 1 46
a=18.5868(12)Å b=6.8213(5)Å c=14.0335(10)Å
α=90.00° β=103.406(4)° γ=90.00°
P50 2-aminopyrazine, (4-NO2-PhCOOH)2
(C4H5N3)(C7H5NO4)2
CrystEngComm (2012) 14, 18 5845
a=13.8994(7)Å b=5.4845(3)Å c=13.1317(6)Å
α=90.00° β=101.948(2)° γ=90.00°
P55 2-aminopyrazine, 3-NO2-PhCOOH
(C4H5N3)(C7H5NO4)2
CrystEngComm (2012) 14, 18 5845
a=5.9930(10)Å b=12.1894(18)Å c=12.995(2)Å
α=90.00° β=98.803(8)° γ=90.00°
P54 2-aminopyrazine, 3,5-(NO2)2-PhCOOH
(C4H5N3)(C7H4N2O6)
CrystEngComm (2012) 14, 18 5845
a=7.6755(11)Å b=8.8822(11)Å c=9.6107(15)Å
α=84.645(10)° β=82.063(11)° γ=74.877(10)°
D3 2-aminopyrazine, HOOC-(CH2)2-COOH
(C4H5N3)2(C4H6O4)
CrystEngComm (2012) 14, 18 5845
a=5.3982(9)Å b=19.505(3)Å c=6.9524(12)Å
α=90.00° β=104.487(10)° γ=90.00°
D9 2-aminopyrazine, HOOC-(CH2)5-COOH
(C4H5N3)(C7H12O4)
CrystEngComm (2012) 14, 18 5845
a=5.0231(5)Å b=34.308(3)Å c=7.4377(8)Å
α=90.00° β=102.850(5)° γ=90.00°
D4 2-aminopyrazine, HOOC-(CH2)8-COOH
(C4H5N3)(C10H18O4)
CrystEngComm (2012) 14, 18 5845
a=5.7935(6)Å b=7.5090(8)Å c=8.7271(8)Å
α=92.984(4)° β=91.952(5)° γ=98.570(5)°
D5 2-aminopyrazine, HOOC-(CH2)6-COOH
(C4H5N3)(C8H14O4)
CrystEngComm (2012) 14, 18 5845
a=7.7749(5)Å b=9.8014(7)Å c=9.2097(6)Å
α=90.00° β=101.560(3)° γ=90.00°
AR-cc-2c-10 2,6-dibromo-3-aminopyrazine, F5-PhCOOH
(C4H3N3Br2)(C7HF5O2)
CrystEngComm (2012) 14, 18 5845
a=15.5511(6)Å b=5.8057(2)Å c=16.0859(6)Å
α=90.00° β=111.0750(10)° γ=90.00°
P9 2-amino-3,5-dibromopyrazine, 3,5-(NO2)2-PhCOOH
(C4H3N3Br2)(C7H4N2O6)
CrystEngComm (2012) 14, 18 5845
a=7.3153(3)Å b=10.4607(4)Å c=10.8371(4)Å
α=65.094(2)° β=83.688(2)° γ=89.742(2)°
ARcc-2c-7 2-amino-3,5-dibromopyrazine, 2,6-difluorobenzoic acid
(C4H3N3Br2)(C7H4O2F2)
CrystEngComm (2012) 14, 18 5845
a=5.6663(5)Å b=13.2299(11)Å c=17.3426(14)Å
α=90.00° β=93.911(4)° γ=90.00°
1-(4-pyridyl)-2-(2,3,5,6-F4-4-I-phenyl)ethene
(C13H6F4NI)
CrystEngComm (2007) 9, 5 421
a=12.0266(5)Å b=10.2443(4)Å c=4.9988(2)Å
α=90.00° β=90.00° γ=90.00°
N7 Cu(F6-acac)2 (1-(4-pyridyl)-2-(2,3,5,6-F4-4-Br- phenyl)ethene)2
Cu(C5HO2F6)2(C13H6F4NBr)2
CrystEngComm (2007) 9, 5 421
a=8.9889(3)Å b=9.0836(3)Å c=12.9622(5)Å
α=88.061(2)° β=86.489(2)° γ=67.894(2)°
NSBrCo Co(F6-acac)2 (1-(4-pyridyl)-2-(2,3,5,6-F4-4-Br- phenyl)ethene)2
Co(C5HO2F6)2(C13H6F4NBr)2
CrystEngComm (2007) 9, 5 421
a=8.9245(4)Å b=9.0077(3)Å c=13.0921(5)Å
α=86.370(2)° β=86.442(2)° γ=70.214(2)°
N3 Cu(F6-acac)2 (1-(4-pyridyl)-2-(2,3,5,6-F4-4-I- phenyl)ethene)2
Cu(C5HO2F6)2(C13H6F4NI)2
CrystEngComm (2007) 9, 5 421
a=9.0352(4)Å b=9.0357(4)Å c=13.2174(6)Å
α=87.447(2)° β=88.530(2)° γ=69.506(2)°
3S (aminopyridyl)ethynylcavitand, NO22PhCOOH
(C80H80N8O8)(C7H4N2O6)4(C2H3N)2.45(C2H5O)0.55
CrystEngComm (2007) 9, 3 211
a=14.636(3)Å b=17.062(3)Å c=25.079(4)Å
α=76.787(10)° β=85.972(12)° γ=64.566(9)°
NS6S (6-amino-3-pyridyl)ethynyl cavitand, glutaric acid
(C5H8O4)2(C80H80N8O8)(C8H10)1.2(C2H3N)
CrystEngComm (2007) 9, 3 211
a=12.7783(9)Å b=24.5634(18)Å c=29.317(2)Å
α=90.00° β=90.00° γ=90.00°
Tetra-(3-pyridyl)ethynyl calixarene
(C80H76N4O8)(C2H3N)(H2O)2
CrystEngComm (2006) 8, 7 502
a=25.359(2)Å b=22.2099(19)Å c=12.1129(10)Å
α=90.00° β=90.00° γ=90.00°
Hexyl bromo calixarene, acetonitrile
(C52H60O8I4)(C2H3N)
CrystEngComm (2006) 8, 7 502
a=19.045(3)Å b=16.627(2)Å c=18.618(3)Å
α=90.00° β=118.047(8)° γ=90.00°
SF229 (3-pyridyl)-CONH-N=CH-(2-pyridyl), 4-nitrobenzoic acid hydrate
(C12H10N4O)(C7H5NO4)(H2O)
CrystEngComm (2012) 14, 7 2435
a=6.5983(13)Å b=7.2343(14)Å c=19.755(4)Å
α=81.922(11)° β=84.772(14)° γ=80.711(16)°
SF41 4-pyridyl-CONH-N=CH-4-pyridyl, succinic acid dihydrate
(C12H10N4O)(C4H6O4)(H2O)2
CrystEngComm (2012) 14, 7 2435
a=4.8122(3)Å b=8.8128(5)Å c=11.0772(6)Å
α=75.874(3)° β=80.095(3)° γ=76.225(3)°
SF40 4-pyridyl-CONH-N=CH-4-pyridyl, octanedioic acid hydrate
(C12H10N4O)(C8H14O4)(H2O)
CrystEngComm (2012) 14, 7 2435
a=6.918(2)Å b=11.800(4)Å c=13.910(5)Å
α=67.522(16)° β=79.851(16)° γ=84.973(16)°
SF355 4-pyridyl-CONH-N=CH-2-pyridyl, 2,4-difluorobenzoic acid hydrate
(C12H10N4O)(C7H4O2F2)(H2O)(O0.1)
CrystEngComm (2012) 14, 7 2435
a=7.4376(2)Å b=12.3798(4)Å c=39.3480(11)Å
α=90.00° β=93.396(2)° γ=90.00°
SF363 [4-pyridyl-CONH-N=CH-2-pyridyl] adipic acid
(C12H10N4O)2(C6H10O4)(H2O)2
CrystEngComm (2012) 14, 7 2435
a=6.6047(8)Å b=8.0678(9)Å c=15.3573(18)Å
α=98.182(6)° β=101.688(8)° γ=104.436(9)°
SF241 formylpyridine phenylhydrazone, octanoic acid, hydrate
(C12H10N4O)(C8H16O2)(H2O)
CrystEngComm (2012) 14, 7 2435
a=6.6610(8)Å b=8.4541(11)Å c=19.684(2)Å
α=99.459(8)° β=94.349(9)° γ=107.887(8)°
SF357 [(3-pyridyl)-CONH-N=CH-(2-pyridyl)]2, octanedioic acid hydrate
(C12H10N4O)2(C8H14O4)(H2O)2
CrystEngComm (2012) 14, 7 2435
a=6.6074(6)Å b=8.1545(7)Å c=15.8735(14)Å
α=81.488(6)° β=83.679(6)° γ=75.024(7)°
SF 356 (4-pyridyl)-CONH-N=CH-(2-pyridyl), decanedioic acid
(C12H10N4O)2(C10H18O4)(H2O)2
CrystEngComm (2012) 14, 7 2435
a=6.5516(4)Å b=8.1666(5)Å c=33.7458(19)Å
α=94.293(3)° β=93.041(3)° γ=105.225(3)°
C20 (4-pyridyl)-CONH-N=CH-(2-pyridyl), 4-aminobenzoic acid hydrate ?
(C12H10N4O)(C7H7NO2)(H2O)
CrystEngComm (2012) 14, 7 2435
a=8.8995(2)Å b=14.6202(4)Å c=14.0267(3)Å
α=90.00° β=93.198(2)° γ=90.00°
3,3'-AzoPy-3HBXB (3-pyridyl)-N=N-(3-pyridyl), (4-I-F4-PhOH)2
(C10H8N4)(C6HF4IO)2
CrystEngComm (2013) 15, 16 3125
a=19.0228(11)Å b=16.8636(10)Å c=7.2425(4)Å
α=90.00° β=93.198(2)° γ=90.00°
3,3'-AzoPy 2-HBXB (3-pyridyl)-N=N-(3-pyridyl), (4-Br-F4- PhCOOH)2
(C10H8N4)(C7HBrF4O2)2
CrystEngComm (2013) 15, 16 3125
a=4.8724(3)Å b=22.0007(13)Å c=11.6936(7)Å
α=90.00° β=101.336(3)° γ=90.00°
3,3'-AzoPy 8-HBXB (3-pyridyl)-N=N-(3-pyridyl), (4-I-F4- PhCH=NOH)2
(C10H8N4)(C7H2F4INO)2
CrystEngComm (2013) 15, 16 3125
a=5.6341(4)Å b=10.4834(7)Å c=11.5197(8)Å
α=75.365(2)° β=77.562(2)° γ=80.975(2)°
3,3'-AzoPy 4-HBXB, (3-pyridyl)-N=N-(3-pyridyl), (4-Br-F4- PhOH)2
(C10H8N4)(C6HBrF4O)2
CrystEngComm (2013) 15, 16 3125
a=18.2149(8)Å b=16.4379(7)Å c=7.4736(4)Å
α=90.00° β=99.631(2)° γ=90.00°
C17H9BrF4N4O2
C17H9BrF4N4O2
CrystEngComm (2013) 15, 16 3125
a=10.1601(6)Å b=13.4584(8)Å c=14.4512(10)Å
α=112.181(4)° β=90.560(4)° γ=111.547(4)°
4,4'-AzoPy 3-HBXB (4-pyridyl)-N=N-(4-pyridyl), 4-I-F4-PhOH
(C10H8N4)(C6HF4IO)
CrystEngComm (2013) 15, 16 3125
a=6.1515(5)Å b=9.8197(7)Å c=13.7443(10)Å
α=81.558(3)° β=85.932(3)° γ=78.342(3)°
4,4'AzoPy 5-HBXB (4-pyridyl)-N=N-(4-pyridyl), (4-Br-F4-PhCHO oxime)2
(C10H8N4)(C7H2BrF4NO)2
CrystEngComm (2013) 15, 16 3125
a=10.2846(10)Å b=4.6215(5)Å c=27.841(2)Å
α=90.00° β=98.246(6)° γ=90.00°
3,3'-AzoPy-SA (3-pyridyl)-N=N-(3-pyridyl), HOOC-(CH2)2-COOH
(C10H8N4)(C4H6O4)
CrystEngComm (2013) 15, 3 463
a=11.9092(7)Å b=5.2342(3)Å c=11.3589(7)Å
α=90.00° β=91.198(3)° γ=90.00°
03-04BD (3-pyridyl)-N=N-(3-pyridyl), HOOC-(CH2)6-COOH
(C10H8N4)(C8H14O4)
CrystEngComm (2013) 15, 3 463
a=5.4680(6)Å b=7.0381(7)Å c=11.9358(12)Å
α=98.867(6)° β=93.592(6)° γ=102.392(6)°
03-03BD (3-pyridyl)-N=N-(3-pyridyl), HOOC-(CH2)8-COOH
(C10H8N4)(C10H18O4)
CrystEngComm (2013) 15, 3 463
a=7.0388(14)Å b=8.2451(18)Å c=17.490(4)Å
α=77.525(14)° β=80.368(13)° γ=85.474(14)°
MS 9-37 1,3,5-tri(C(CN)=NOH)benzene, 1,4-di(4-pyridyl)ethane
(C12H6N6O3)2(C12H12N2)3(C2H3N)2.25
CrystEngComm (2012) 14, 1 71
a=11.310(2)Å b=17.162(3)Å c=17.335(3)Å
α=88.010(10)° β=82.742(10)° γ=70.891(10)°
Bis(2-amino-4-(3-pyridyl)-6-methylpyrimidine) mu- (OAc)4dicopper(ii)
(C10H10N4)2Cu2(C2H3O2)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.0282(5)Å b=10.6399(7)Å c=18.9041(13)Å
α=90.00° β=99.3600(10)° γ=90.00°
Bis(2-amino-4-(3-pyridyl)-6-methoxypyrimidine) mu-(OAc)4 dicopper(ii)
(C10H10N4O)2Cu2(C2H3O2)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.2800(6)Å b=9.3983(6)Å c=11.2233(7)Å
α=71.144(4)° β=81.585(4)° γ=79.240(4)°
(2-amino-4-(3-pyridyl)-6-methoxypyridine)2, (2- fluorobenzoate)4 Cu2
(C10H10N4O1)2(C7H4O2F)4Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=10.1310(9)Å b=10.5499(8)Å c=12.2936(9)Å
α=64.853(5)° β=86.149(5)° γ=67.896(4)°
(2-amino-4-(3-pyridyl)-6-methylpyridine)2, (2FPhCOO)4 Cu2
(C10H10N4)2Cu2(C7H4O2F)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=21.3553(18)Å b=17.9389(15)Å c=11.4887(9)Å
α=90.00° β=90.742(5)° γ=90.00°
1-(2-NH2-5-pyridyl)-2-(3-pyridyl)-ethyne, (CH3COO)4Cu2
(C12H9N3)Cu2(C2H3O2)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.1368(11)Å b=8.3062(11)Å c=8.7490(12)Å
α=86.244(3)° β=80.480(3)° γ=80.539(3)°
1-(2-NH2-5-pyridyl)-2-(3-pyridyl)-ethyne, (2FPhCOO)4Cu2
(C12H9N3)Cu2(C7H4O2F)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=9.3471(9)Å b=15.5850(15)Å c=12.9025(11)Å
α=90.00° β=104.714(7)° γ=90.00°
1-(2-NH2-4-pyrimidyl)-2-(3-methoxy-5-pyridyl)ethyne (AcO)4Cu2 (EtO).6 (CH3CN).8
(C34H36Cu2N8O10)(C2H5O)0.6(C2H3N)0.8
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=7.6304(13)Å b=11.3870(19)Å c=12.341(2)Å
α=76.216(3)° β=84.191(3)° γ=79.459(3)°
2,2-bis(benzanthracenol imine)binaphthyl, dichloromethane
(C58H36N2O2)(CH2Cl2)
Dalton transactions (Cambridge, England : 2003) (2007) 15 1520-1527
a=8.8321(14)Å b=11.5748(18)Å c=42.316(7)Å
α=90.00° β=90.00° γ=90.00°
(2,2-bis(benzanthracenol imine)binaphthyl Fe(ii)) (Et2O)
(C58H34N2O2Fe)(C4H10O)
Dalton transactions (Cambridge, England : 2003) (2007) 15 1520-1527
a=12.6954(3)Å b=12.6954(3)Å c=24.3493(10)Å
α=90.00° β=90.00° γ=120.00°
2-formylbenzoquinoline
C14H9NO
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=7.4691(10)Å b=19.748(3)Å c=6.9392(11)Å
α=90.00° β=105.028(9)° γ=90.00°
1,2-bis(benzoquinoline imine) cyclohexane
C34H28N4
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=6.6519(2)Å b=6.6519(2)Å c=56.855(3)Å
α=90.00° β=90.00° γ=90.00°
Bis(benzoquinoline imine)cyclohexane ZnCl2 (dichloromethane)2
(C34H28N4Cl4Zn2)(CH2Cl2)2
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=15.0432(14)Å b=17.1668(17)Å c=15.9752(14)Å
α=90.00° β=111.564(4)° γ=90.00°
AL-3-163
C74H70Cl4N4Zn2
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=17.5549(10)Å b=11.7013(7)Å c=17.5582(11)Å
α=90.00° β=116.636(3)° γ=90.00°
AL-3-190 cyclohexanediamine bis(8-iPr-quinoline-1-CHO imine)
(C32H36N4Cl4Zn2)(CH2Cl2)
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=13.045(3)Å b=13.450(3)Å c=14.109(3)Å
α=116.747(14)° β=91.053(12)° γ=115.182(15)°
Bis(3-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4
(C16H15N3O)2(AgBF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.666(2)Å b=12.237(2)Å c=13.013(2)Å
α=109.136(13)° β=114.266(8)° γ=92.310(14)°
Bis(4-((6,7-dimethylbenzimidazol-1-yl)methyl)benzamide), AgBF4
(C17H17N3O)2Ag(BF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.9140(7)Å b=8.4229(6)Å c=19.7055(13)Å
α=90.00° β=102.108(3)° γ=90.00°
(4-((5,6-dimethylbenzimidazol-1-yl)methyl)benzamide)2, AgAsF6
(C17H17N3O)2AgAsF6
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.1269(6)Å b=9.2459(5)Å c=10.0615(7)Å
α=97.921(4)° β=89.950(4)° γ=98.904(4)°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.3084(4)Å b=18.5828(11)Å c=25.1620(15)Å
α=90.00° β=96.8060(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)(O)3
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.5069(5)Å b=18.6924(12)Å c=24.9808(17)Å
α=90.00° β=98.4920(10)° γ=90.00°